Effector Therapeutics Inc (EFTR) — Cash Flow-to-Debt Ratio
Effector Therapeutics Inc (EFTR) has a Cash Flow-to-Debt Ratio of -0.28x as of March 2024, meaning its operating cash flow of $-7.28 Million could theoretically repay 0% of its total liabilities ($26.30 Million) in one year. See free cash flow generation of Effector Therapeutics Inc to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Effector Therapeutics Inc Cash Flow-to-Debt Ratio (2019–2023)
Historical debt coverage capacity for Effector Therapeutics Inc across 5 annual periods. Also explore Effector Therapeutics Inc net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Effector Therapeutics Inc (2019–2023)
Year-by-year debt coverage analysis for Effector Therapeutics Inc. For market capitalisation and broader financial context, see Effector Therapeutics Inc (EFTR) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2023 | -1.12x | $-29.55 Million | $26.34 Million | ▼ -9.1% |
| 2022 | -1.03x | $-25.90 Million | $25.18 Million | ▼ -52.0% |
| 2021 | -0.68x | $-24.89 Million | $36.77 Million | ▼ -828.7% |
| 2020 | 0.09x | $13.84 Million | $148.95 Million | ▲ +106.4% |
| 2019 | -1.46x | $-27.60 Million | $18.93 Million | — |